RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
1-Year Return
12.81%
This Quarter Return
+18.53%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.06B
AUM Growth
+$54.1M
(+5.4%)
Cap. Flow
-$61M
Cap. Flow
% of AUM
-5.78%
Top 10 Holdings %
Top 10 Hldgs %
34.88%
Holding
95
New
10
Increased
31
Reduced
41
Closed
11
Top Buys
| 1 |
Cigna
CI
|
$32.7M |
| 2 |
Elevance Health
ELV
|
$29.3M |
| 3 |
Becton Dickinson
BDX
|
$28.7M |
| 4 |
Penumbra
PEN
|
$9.71M |
| 5 |
Merck
MRK
|
$9.37M |
Top Sells
| 1 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$24.7M |
| 2 |
Medtronic
MDT
|
$23.2M |
| 3 |
Eli Lilly
LLY
|
$18.5M |
| 4 |
Humana
HUM
|
$17.9M |
| 5 |
Danaher
DHR
|
$16.7M |
Sector Composition
| 1 | Healthcare | 99.69% |
| 2 | Industrials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Align Technology
ALGN
$9.76B
| $16.4M | 1.55% |
50,000
+23,000
| +85% | +$7.54M |
|
27
Dynavax Technologies
DVAX
$1.17B
| $14.4M | 1.36% |
1,157,361
+357,361
| +45% | +$4.43M |
|
28
Iovance Biotherapeutics
IOVA
$796M
| $14.2M | 1.34% |
955,000
-161,818
| -14% | -$2.4M |
|
29
Cytokinetics
CYTK
$5.95B
| $13.8M | 1.31% |
197,515
+47,603
| +32% | +$3.34M |
|
30
Biogen
BIIB
$20.5B
| $12.2M | 1.16% |
56,800
-1,872
| -3% | -$404K |
|
31
Viking Therapeutics
VKTX
$2.98B
| $11.9M | 1.13% |
145,000
-35,000
| -19% | -$2.87M |
|
32
Axsome Therapeutics
AXSM
$6.21B
| $11.5M | 1.09% |
143,600
+64,500
| +82% | +$5.15M |
|
33
Apellis Pharmaceuticals
APLS
$3.62B
| $10.5M | 0.99% |
178,395
+77,995
| +78% | +$4.58M |
|
34
Cencora
COR
$56.7B
| $10.3M | 0.98% |
42,500
-53,500
| -56% | -$13M |
|
|
35
Penumbra
PEN
$10.9B
| $10.3M | 0.97% |
46,000
+43,500
| +1,740% | +$9.71M |
|
36
Centene
CNC
$14.1B
| $10.1M | 0.96% |
129,000
-6,000
| -4% | -$471K |
|
37
Alignment Healthcare
ALHC
$3.23B
| $10M | 0.95% |
2,022,736
+1,072,736
| +113% | +$5.32M |
|
38
Exact Sciences
EXAS
$9.73B
| $9.88M | 0.94% |
143,000
-22,000
| -13% | -$1.52M |
|
39
Madrigal Pharmaceuticals
MDGL
$9.61B
| $9.75M | 0.92% |
36,500
+14,000
| +62% | +$3.74M |
|
|
ITCI
40
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $9.52M | 0.9% |
137,500
+47,500
| +53% | +$3.29M |
|
41
Gilead Sciences
GILD
$140B
| $9.3M | 0.88% |
127,000
-132,000
| -51% | -$9.67M |
|
42
Inspire Medical Systems
INSP
$2.55B
| $9.02M | 0.86% |
42,000
+24,000
| +133% | +$5.15M |
|
43
Zimmer Biomet
ZBH
$20.8B
| $8.91M | 0.84% |
67,500
+12,500
| +23% | +$1.65M |
|
44
Neurocrine Biosciences
NBIX
$13.9B
| $8.14M | 0.77% |
59,000
-3,000
| -5% | -$414K |
|
45
IQVIA
IQV
$31.3B
| $7.84M | 0.74% |
31,000
-14,000
| -31% | -$3.54M |
|
46
NovoCure
NVCR
$1.34B
| $7.74M | 0.73% |
495,307
+335,307
| +210% | +$5.24M |
|
47
ESSA Pharma
EPIX
$11M
| $7.74M | 0.73% |
911,820
+555,320
| +156% | +$4.71M |
|
48
Thermo Fisher Scientific
TMO
$185B
| $7.56M | 0.72% |
13,000
-20,500
| -61% | -$11.9M |
|
49
Arvinas
ARVN
$559M
| $7.02M | 0.67% |
170,000
+35,730
| +27% | +$1.47M |
|
50
Nuvalent
NUVL
$5.74B
| $6.57M | 0.62% |
87,500
-25,429
| -23% | -$1.91M |
|